Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Since the adoption of the new terminology from the Delphi Consensus statement, there has not been a large multicenter cohort study of MASLD among lean versus non-lean individuals. This study aims to assess prevalence and incidence outcomes among lean and non-lean individuals with MASLD in a diverse patient cohort.
Methods: We conducted a retrospective multicenter study on patients with MASLD at the Banner and the University of Michigan Health systems from 2012 to 2023. Main outcomes included mortality and incidence of cirrhosis, cardiovascular disease (CVD), major adverse liver outcome (MALO), and cancer.
Results: Seventy-five thousand nine hundred twenty-one patients were included in this cohort with 5% lean individuals. In this cohort, 4.99% were lean, 23.16% were overweight, 28.47% were obesity class I, and 43.39% were obesity class II-III; 58.49% were female; and 66.32% were non-Hispanic White, 22.23% Hispanic, 4.75% Black, 1.71% Native Americans (NAs), and 1.97% Asian/Pacific Islander. After adjusting for confounders, lean individuals had a higher mortality, higher incidence of CVD, and higher incidence of MALO.
Conclusions: Lean individuals have a higher mortality, higher cardiovascular burden, and higher incidence of MALO compared to non-lean individuals. Further studies are warranted to explore lean patients with MASLD, and interventions are needed to decrease mortality in this patient population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366643 | PMC |
| http://dx.doi.org/10.1111/jgh.17015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients.
Sci Rep
August 2025
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
While metabolic dysfunction-associated fatty liver disease (MAFLD) includes the homeostatic model assessment for insulin resistance (HOMA-IR) as one of the criteria to define metabolic dysregulation, the newly proposed metabolic dysfunction-associated steatotic liver disease (MASLD) has removed this criterion. We investigated whether the HOMA-IR can serve as an independent predictive marker for significant fibrosis in subjects with MAFLD. This is a cross-sectional multicenter study.
View Article and Find Full Text PDFMulti-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease.
Nat Metab
July 2025
Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition linked to obesity and the metabolic syndrome, yet its transkingdom connections have been under-investigated. We performed high-resolution multi-omic profiling-including stool metagenomes, metatranscriptomes and metabolomes-in 211 MASLD cases and 502 controls from a cohort of female nurses. Here we show that MASLD is associated with shifts in 66 gut bacterial species, including widespread enrichment of oral-typical microbes, and transkingdom dysbiosis involving not only bacterial but also viral taxa.
View Article and Find Full Text PDFAssociation of lean metabolic dysfunction-associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus.
J Diabetes Investig
September 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
Introduction: We aimed to investigate whether lean metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus.
Materials And Methods: We investigated 828 patients with type 2 diabetes mellitus who underwent baseline abdominal and carotid artery ultrasonography, followed by repeat carotid ultrasonography after 6-8 years. MASLD was confirmed by abdominal ultrasonography, and lean body mass was defined as a body mass index <23 kg/m.
Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study.
J Gastroenterol Hepatol
August 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, Arizona, USA.
Background And Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Since the adoption of the new terminology from the Delphi Consensus statement, there has not been a large multicenter cohort study of MASLD among lean versus non-lean individuals. This study aims to assess prevalence and incidence outcomes among lean and non-lean individuals with MASLD in a diverse patient cohort.
View Article and Find Full Text PDFExplicit and implicit affective attitudes of female athletes towards different body sizes.
BMC Psychol
March 2025
Faculty of Human Science, University of Regensburg, Universitätstraße 31, 93053, Regensburg, Germany.
The present cross-sectional study is the first to investigate the relationship between implicit and explicit attitudes toward different body sizes in female athletes of different sport types. Second, it was examined if these attitudes are, among other factors, related to body satisfaction in these women. In total, 146 female athletes between 18 and 65 from lean and non-lean sports participated in the study, measuring explicit and implicit affective attitudes using pictures of women with different body sizes.
View Article and Find Full Text PDF